OccuLogix completes patient enrolment for glaucoma laser trial

Article

OccuLogix today announced the completion of enrolment for the SOLX 790 titanium laser trabeculoplasty (TLT) clinical trial, which the firm hopes will support its application for 510(k) clearance with the FDA.

OccuLogix today announced the completion of enrolment for the SOLX 790 titanium laser trabeculoplasty (TLT) clinical trial, which the firm hopes will support its application for 510(k) clearance with the FDA.

SOLX 790 is already commercially available in Europe and Canada.

The laser is currently being assessed for intraocular pressure (IOP) reduction ability in comparison to argon laser trabeculoplasty (ALT). According to the firm, TLT has so far shown consistent, equivalent IOP reduction in patients followed for up to one year in a randomised study.

The current trial is a US FDA, multicentre, outpatient study assessing equivalency of TLT to ALT in IOP reducing ability in primary open angle glaucoma patients who are poorly controlled on maximally tolerated medications and/or who have failed prior glaucoma surgery. More than 160 eyes have been enrolled in sites across the US and Canada and also in Israel and Spain. Half of patients have been randomised to receive TLT therapy.

"In my experience, patients treated with SOLX 790 achieve an immediate reduction in IOP and these levels are maintained for up to 12 months," according to Israeli investigator Modi Goldenfeld, MD. "The ability of this laser to lower and maintain IOP levels without causing thermal damage is very important."

The SOLX 790 laser is a titanium-sapphire laser that emits near-infrared light at the 790 nm level to loosen particles in the trabecular meshwork, without causing thermal damage, and penetrating deep into tissue, to a depth of approximately 200 microns. According to CEO and Founder of SOLX, Doug Adams, this is the first laser of its kind to demonstrate these features.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.